0000000000824856

AUTHOR

María-josé Terol

showing 2 related works from this author

A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with…

2017

Here we report the applicability of a protocol based on clinical conditions and risk factors (RFs) for managing 35 allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients who developed a total of 52 episodes of respiratory viral infections (RVIs) caused by respiratory syncytial virus (RSV; n=19), human parainfluenza virus (HPIV; n=29), or both (n=4) over a 2-year study period. Risk categories were classified as high risk (cat-1) when the immunodeficiency scoring index was >= 3 and/or >= 3 RFs and/or >= 1 co-infective virus(es) were present; the remaining cases were classified as low risk (cat-0). The presence of two or more signs or symptoms including fever (T>38 degrees C…

AdultMale0301 basic medicinemedicine.medical_specialtyrespiratory syncytial virus030106 microbiologyTonsillitisAdministration OralPilot ProjectsRespiratory Syncytial Virus InfectionsAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineLower respiratory tract infectionRibavirinmedicineHumansECIL-4allogeneic hematopoietic stem cell transplantationhuman parainfluenza virusProspective Studiesrespiratory viral infectionSinusitisimmunodeficiency scoring indexImmunodeficiencyAgedTransplantationParamyxoviridae InfectionsRespiratory tract infectionsbusiness.industryRibavirinHematopoietic Stem Cell TransplantationMiddle Agedmedicine.diseaseTransplantationHuman Parainfluenza VirusInfectious DiseaseschemistryImmunologyoral ribavirinFemalebusinessStem Cell Transplantation030215 immunology
researchProduct

Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection

2015

Abstract Aggressive B-cell Lymphomas are the second most frequent AIDS-defining cancers. Few studies have compared the molecular characteristics of aggressive B-cell lymphomas in patients with and without HIV-infection; and to our knowledge, there are no reports comparing the incidence of gene rearrangements between the two groups and their impact on outcome in series treated with RCHOP. We retrospectively studied two series of patients with (N=32) and without HIV-infection (N=43) with diffuse large B-cell lymphomas (DLBCL) NOS (75% and 70%, respectively), T-rich DLCBL (13% and 5%), transformed DLBCL (3% and 14%) and double-hit (DH) DLCBL (9% and 11%) [defined by translocations affecting MY…

medicine.medical_specialtyPathologybusiness.industryIncidence (epidemiology)ImmunologyFollicular lymphomaCell BiologyHematologyCHOPmedicine.diseaseBiochemistryGastroenterologyLymphomaExact testInternational Prognostic IndexInternal medicinemedicineProgression-free survivalbusinessDiffuse large B-cell lymphomaBlood
researchProduct